LipoEdge Highlights Published Research on Advanced Liposomal Zinc Formulation

Study reports 94.51% encapsulation efficiency, 203.1 nm particle size, and stable encapsulation over six months.
 
KOLKATA, India - Oct. 9, 2026 - PRLog -- LipoEdge highlights published research on WBCIL's phosphatidylcholine-based Liposomal Zinc formulation. The study evaluated formulation characteristics, encapsulation efficiency, particle size, surface charge, morphology, and stability.

Researchers reported 94.51% encapsulation efficiency for the Liposomal Zinc formulation. Dynamic light scattering measured a mean particle size of 203.1 nm and a PDI of 0.3344. The formulation also showed a zeta potential of −40.79 mV.

Multiple Analytical Measurements Support Formulation Characterization

The study used dynamic light scattering, zeta potential analysis, SEM, EDAX, FTIR, HPLC, and sieve analysis to examine particle characteristics, morphology, elemental composition, and formulation performance.

Six-Month Stability Evaluation

The study examined formulation stability for six months at 40°C ± 2°C and 75% ± 5% relative humidity. Encapsulation efficiency remained between 94.32% and 95% throughout the evaluation. Assay values changed from 20.07% at baseline to 20.04% after six months.

Thermal Stress Testing

Researchers tested the formulation at 105°C for four hours. Encapsulation efficiency changed from 94.51% before exposure to 94% after exposure, while assay values changed from 20.07% to 20.04%.

Sieve Analysis Adds Another Formulation Parameter

Researchers evaluated formulation fractions using sieve sizes ranging from 400 µm to 44 µm. At 400 µm, 99.91% of the formulation passed through the mesh, decreasing to 2.45% at 44 µm. Encapsulation efficiency remained between 94% and 95% across the evaluated fractions. Sieve results describe formulation fractions, not individual vesicle diameter.

Separating Formulation Data from Clinical Evidence

The paper cites external clinical research involving 20 healthy volunteers who received a single 25 mg zinc dose. The study reported 3.82-fold higher bioavailability for its liposomal product versus non-liposomal zinc. These findings do not establish equivalent bioavailability for WBCIL's formulation.

About LipoEdge

LipoEdge represents WBCIL's liposomal formulation know-how and development capabilities, including formulation development, optimization, characterization and analytical evaluation.

About WBCIL

West Bengal Chemical Industries Limited develops and manufactures pharmaceutical and nutraceutical ingredients. WBCIL maintains WHO-GMP, cGMP, ISO, HACCP, and GLP certifications and received the National IP Award in 2024 in the MSME category.

Scientific Reference

Gupta Banerjee P, Paul A, Chakraborty A, Kundu S. 2025.


"Liposomal Zinc Supplementation Formulated by WBCIL to Enhance Bioavailability and Therapeutic Potential in Health and Disease Management."

World Journal of Pharmaceutical Science and Research, 4(3), 1418–1435.

DOI: 10.5281/zenodo.15806571

Research: https://www.thelipoedge.com/journals/

Liposomal Zinc: https://www.thelipoedge.com/product/liposomal-pharmaceuticals/liposomal-zinc/

Connect with WBCIL to discuss your liposomal zinc formulation, development and manufacturing requirements.

AG-112, Room No. 604, 6th Floor, Sector-II, Baishaki, Bidhannagar, Salt Lake, Kolkata, West Bengal 700091
+913340251539
Location: https://share.google/AmdYkdvlNq3BqWkOQ

Contact
LipoEdge
info@thelipoedge.com
06290900900
End
Source: » Follow
Email:***@thelipoedge.com
Posted By:***@thelipoedge.com Email Verified
Tags:Liposomal Zinc Formulation
Industry:Manufacturing
Location:Kolkata - West Bengal - India
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Oct 15, 2026
LipoEdge PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share